Rallybio (RLYB) investor relations material

Opening remarks and agenda

• Virtual meeting called to order on Nov. 4, 2026; 4,790,320 votes represented ~90% of voting power as of the Sept. 11 record date, establishing a quorum.

• Nine proposals were presented for stockholder consideration; the meeting was conducted virtually, with questions on proposals and voting procedures submitted through the web portal.

Board and executive committee updates

• Class II nominees Viva Newton, Helen Boudreau, Lucian Iancovici and Christine Nash were elected to serve until the 2029 AGM, subject to earlier departure or successor qualification.

Shareholder proposals

• Proposal 1 sought approval to issue shares to Avenzo Therapeutics holders, representing more than 20% of pre-merger outstanding shares and resulting in a change of control under Nasdaq rules.

• Proposed charter changes included a 1-for-2 to 1-for-9 reverse split, with the ratio to be determined jointly with Avenzo, and a name change to Avenzo Therapeutics Inc.

• A charter amendment proposed increasing authorized common shares from 200 million to 500 million.

• Merger-contingent proposals covered the Avenzo 2026 Equity Incentive Plan and Employee Stock Purchase Plan, effective the day after merger completion.

• Proposal 9 sought authority to adjourn the meeting if needed to solicit additional proxies for proposals 1–4.